PhRMA Launches New Website to Provide Patients with Medicine Cost Information
Washington, D.C. (May 8, 2019) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Steven J. Ubl issued the…
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Cuker A1, Bass AD2, Nadj C3, Agius MA4, Steingo B5, Selmaj KW6, Thoits T7, Guerreiro A8, Van Wijmeersch B9, Ziemssen T10, Meuth SG11, LaGanke CC12, Thangavelu K13, Rodriguez CE13,14, Baker DP13, Margolin DH13,15, Jannsens A16. Author…
Stuart Schlossman
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease.
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease. This…
Stuart Schlossman
Mapi Pharma to Host Key Opinion Leader Meeting on LONG ACTING Glatiramer Acetate (GA Depot) for Primary Progressive Multiple Sclerosis and New Treatments for MS
NESS ZIONA, Israel, Feb. 21, 2019 (GLOBE NEWSWIRE) — Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company,…
Stuart Schlossman
Early Treatment Shows Lower Risk to Secondary Progressive MS
All therapies best placebo, prospective study shows by Judy George, Contributing Writer, MedPage TodayJanuary 15, 2019 Multiple sclerosis (MS) patients treated initially…
Stuart Schlossman
Can MS Treatment Be Stopped?
Pendulum keeps swinging on risks from drug discontinuation by Judy George, Contributing Writer, MedPage Today March 04, 2019 DALLAS —…
Stuart Schlossman
Scientists spot warning signs for multiple sclerosis
December 27, 2018 The presence of certain levels of a molecule called acrolein in the human body could be an…
Stuart Schlossman
Video: A prediction for the Future of MS Therapeutics [2019]
In this video Aaron Boster, MD, predicts the future, of the MS therapeutic landscape! If you’d like to hear his…
Stuart Schlossman
Pretreating Ocrevus Patients with Multiple Antihistamines and Liquids Lowers Infusion Reactions by 60%, Study Reports
December 18, 2018 Pretreating multiple sclerosis patients with antihistamines more extensively and with hydration can significantly reduce — by 60% — the likelihood…
Stuart Schlossman
Cladribine (also known as Mavenclad™)
Experimental Medications: Administered Orally Company: Merck Oral medication taken for a maximum of 20 days over two years Being studied…
Stuart Schlossman
